{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:28:21Z","timestamp":1671535701442},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T00:00:00Z","timestamp":1287532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10549-010-1214-3","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T10:09:02Z","timestamp":1287482942000},"page":"127-136","source":"Crossref","is-referenced-by-count":4,"title":["Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients"],"prefix":"10.1007","volume":"125","author":[{"given":"Mathias","family":"Warm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Overkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.ejca.2006.06.022","volume":"42","author":"A Milano","year":"2006","unstructured":"Milano A, Dal Lago L, Sotiriou C et al (2006) What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 42:2692\u20132705","journal-title":"Eur J Cancer"},{"key":"1214_CR2","doi-asserted-by":"crossref","first-page":"vi53","DOI":"10.1093\/annonc\/mdm225","volume":"18","author":"V Adamo","year":"2007","unstructured":"Adamo V, Iorfida M, Montalto E et al (2007) Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol 18:vi53\u2013vi57","journal-title":"Ann Oncol"},{"key":"1214_CR3","first-page":"511S","volume":"9","author":"H Kurokawa","year":"2003","unstructured":"Kurokawa H, Arteaga CL (2003) ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanism. Clin Cancer Res 9:511S\u2013515S","journal-title":"Clin Cancer Res"},{"key":"1214_CR4","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ctrv.2005.08.007","volume":"31","author":"A Howell","year":"2005","unstructured":"Howell A (2005) The future of fulvestrant (\u201cFaslodex\u201d). Cancer Treat Rev 31:S26\u2013S33","journal-title":"Cancer Treat Rev"},{"key":"1214_CR5","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867\u20133873","journal-title":"Cancer Res"},{"key":"1214_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0070017","volume":"7","author":"AE Wakeling","year":"2000","unstructured":"Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Relat Cancer 7:17\u201328","journal-title":"Endocr Relat Cancer"},{"key":"1214_CR7","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1073\/pnas.87.17.6883","volume":"87","author":"SE Fawell","year":"1990","unstructured":"Fawell SE, White R, Hoare S et al (1990) Inhibition of estrogen receptor-DNA binding by the \u2018\u2018pure\u2019\u2019 antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883\u20136887","journal-title":"Proc Natl Acad Sci USA"},{"key":"1214_CR8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1242\/jcs.106.4.1377","volume":"106","author":"S Dauvois","year":"1993","unstructured":"Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377\u20131388","journal-title":"J Cell Sci"},{"key":"1214_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1749-6632.1995.tb31376.x","volume":"761","author":"RI Nicholson","year":"1995","unstructured":"Nicholson RI, Gee JM, Manning DL et al (1995) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann NY Acad Sci 761:148\u2013163","journal-title":"Ann NY Acad Sci"},{"key":"1214_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0959-8049(95)00517-X","volume":"32A","author":"RA McClelland","year":"1996","unstructured":"McClelland RA, Gee JM, Francis AB et al (1996) Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A:413\u2013416","journal-title":"Eur J Cancer"},{"issue":"Suppl. 1","key":"1214_CR11","first-page":"S12","volume":"82","author":"RJ Pietras","year":"2003","unstructured":"Pietras RJ, Marquez DC, Chen HW et al (2003) Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2\/neu gene. Breast Cancer Res Treat 82(Suppl. 1):S12","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bjc.1996.357","volume":"74","author":"A Howell","year":"1996","unstructured":"Howell A, DeFriend DJ, Robertson JF et al (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300\u2013308","journal-title":"Br J Cancer"},{"key":"1214_CR13","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","volume":"20","author":"CK Osborne","year":"2002","unstructured":"Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386\u20133395","journal-title":"J Clin Oncol"},{"key":"1214_CR14","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A Howell","year":"2002","unstructured":"Howell A, Robertson JF, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396\u20133403","journal-title":"J Clin Oncol"},{"key":"1214_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","volume":"98","author":"JF Robertson","year":"2003","unstructured":"Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229\u2013238","journal-title":"Cancer"},{"key":"1214_CR16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664\u20131670","journal-title":"J Clin Oncol"},{"key":"1214_CR17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","volume":"22","author":"A Howell","year":"2004","unstructured":"Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605\u20131613","journal-title":"J Clin Oncol"},{"key":"1214_CR18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.2910550529","volume":"55","author":"XF Hu","year":"1993","unstructured":"Hu XF, Veroni M, De Luise M et al (1993) Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. Int J Cancer 55:873\u2013876","journal-title":"Int J Cancer"},{"key":"1214_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2004.03.005","volume":"220","author":"CT Freddie","year":"2004","unstructured":"Freddie CT, Christensen GL, Lykkesfeldt AE (2004) A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. Mol Cell Endocrinol 220:97\u2013107","journal-title":"Mol Cell Endocrinol"},{"key":"1214_CR20","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1158\/1078-0432.CCR-06-3050","volume":"13","author":"R Bartsch","year":"2007","unstructured":"Bartsch R, Wenzel C, Altorjai G et al (2007) Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 13:4435\u20134439","journal-title":"Clin Cancer Res"},{"key":"1214_CR21","doi-asserted-by":"crossref","unstructured":"Robertson JF, A. Agrawal A, Gutteridge E et al (2006) Correlation of CA15.3 levels with clinical response in advanced breast cancer (ABC) patients receiving fulvestrant. J Clin Oncol 24:18S (abstr 641)","DOI":"10.1200\/jco.2006.24.18_suppl.641"},{"key":"1214_CR22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3816\/CBC.2006.n.036","volume":"7","author":"D Dodwell","year":"2006","unstructured":"Dodwell D, Pippen J (2006) Time to response: comparison of fulvestrant and oral endocrine agents. Clin Breast Cancer 7:244\u2013247","journal-title":"Clin Breast Cancer"},{"key":"1214_CR23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0959-8049(03)00199-0","volume":"39","author":"L Mauriac","year":"2003","unstructured":"Mauriac L, Pippen JE, Quaresma Albano J et al (2003) Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39:1228\u20131233","journal-title":"Eur J Cancer"},{"key":"1214_CR24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10549-008-0132-0","volume":"115","author":"R Bartsch","year":"2009","unstructured":"Bartsch R, Mlineritsch B, Gnant M et al (2009) The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 115:373\u2013380","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-006-9482-7","volume":"106","author":"B Mlineritsch","year":"2007","unstructured":"Mlineritsch B, Psenak O, Mayer P et al (2007) Fulvestrant (\u2018Faslodex\u2019) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Breast Cancer Res Treat 106:105\u2013112","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-008-0141-z","volume":"117","author":"L Mauriac","year":"2009","unstructured":"Mauriac L, Romieu G, Bines J (2009) Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 117:69\u201375","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR27","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.breast.2007.12.004","volume":"17","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W (2008) Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast 17:S16\u2013S21","journal-title":"Breast"},{"issue":"14","key":"1214_CR28","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"key":"1214_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10549-008-0294-9","volume":"117","author":"MP Lux","year":"2009","unstructured":"Lux MP, Hartmann M, Jackisch C et al (2009) Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat 117:305\u2013317","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-009-0452-8","volume":"118","author":"O Freedman","year":"2009","unstructured":"Freedman O, Amir E, Dranitsaris G et al (2009) Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Res Treat 118:377\u2013383","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR31","doi-asserted-by":"crossref","unstructured":"Mello CA, Chinen LT, da Silva SC et al (2010) Prolonged time to progression with fulvestrant for metastatic breast cancer. Med Oncol. doi: 10.1007\/s12032-010-9469-4","DOI":"10.1007\/s12032-010-9469-4"},{"key":"1214_CR32","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","volume":"27","author":"JF Robertson","year":"2009","unstructured":"Robertson JF, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27:4530\u20134535","journal-title":"J Clin Oncol"},{"key":"1214_CR33","doi-asserted-by":"crossref","unstructured":"Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase iii trial comparing fulvestrant 250\u00a0mg with fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. doi: 10.1200\/JCO.2010.28.8415","DOI":"10.1200\/JCO.2010.28.8415"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1214-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1214-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T02:35:30Z","timestamp":1636684530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1214-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1214-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]}}}